{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T10:11:42Z","timestamp":1789726302432,"version":"4.0.1"},"reference-count":70,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2014,2,1]],"date-time":"2014-02-01T00:00:00Z","timestamp":1391212800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Diagnostic Microbiology and Infectious Disease"],"published-print":{"date-parts":[[2014,2]]},"DOI":"10.1016\/j.diagmicrobio.2013.10.011","type":"journal-article","created":{"date-parts":[[2013,10,22]],"date-time":"2013-10-22T09:31:53Z","timestamp":1382434313000},"page":"178-187","source":"Crossref","is-referenced-by-count":27,"title":["Aminoglycoside dosing in patients by kidney function and area under the curve: the Sawchuk-Zaske dosing method revisited in the era of obesity"],"prefix":"10.1016","volume":"78","author":[{"given":"Manjunath P.","family":"Pai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keith A.","family":"Rodvold","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.diagmicrobio.2013.10.011_bb0005","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1111\/j.1365-2125.1989.tb05431.x","article-title":"Population pharmacokinetics of tobramycin","volume":"28","author":"Aarons","year":"1989","journal-title":"Br J Clin Pharmacol"},{"issue":"6","key":"10.1016\/j.diagmicrobio.2013.10.011_bb0010","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1086\/665724","article-title":"Trends in aminoglycoside use and gentamicin-resistant gram-negative clinical isolates in US academic medical centers: implications for antimicrobial stewardship","volume":"33","author":"Ababneh","year":"2012","journal-title":"Infect Control Hosp Epidemiol"},{"issue":"5","key":"10.1016\/j.diagmicrobio.2013.10.011_bb0015","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1128\/AAC.22.5.800","article-title":"Two-compartment comparison of gentamicin and tobramycin in normal volunteers","volume":"22","author":"Adelman","year":"1982","journal-title":"Antimicrob Agents Chemother"},{"issue":"5","key":"10.1016\/j.diagmicrobio.2013.10.011_bb0020","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1038\/clpt.2009.191","article-title":"Nephropharmacology: drugs and the kidney","volume":"86","author":"Atkinson","year":"2009","journal-title":"Clin Pharmacol Ther"},{"issue":"6","key":"10.1016\/j.diagmicrobio.2013.10.011_bb0025","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1111\/j.1445-5994.2011.02452.x","article-title":"Current use of aminoglycosides: indications, pharmacokinetics and monitoring for toxicity","volume":"41","author":"Avent","year":"2011","journal-title":"Intern Med J"},{"issue":"1","key":"10.1016\/j.diagmicrobio.2013.10.011_bb0030","doi-asserted-by":"crossref","first-page":"32","DOI":"10.2165\/00003088-199427010-00004","article-title":"What is the evidence for once-daily aminoglycoside therapy?","volume":"27","author":"Barclay","year":"1994","journal-title":"Clin Pharmacokinet"},{"issue":"4","key":"10.1016\/j.diagmicrobio.2013.10.011_bb0035","first-page":"519","article-title":"Amikacin pharmacokinetics in morbidly obese patients","volume":"37","author":"Bauer","year":"1980","journal-title":"Am J Hosp Pharm"},{"issue":"5","key":"10.1016\/j.diagmicrobio.2013.10.011_bb0040","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1007\/BF00542215","article-title":"Influence of weight on aminoglycoside pharmacokinetics in normal weight and morbidly obese patients","volume":"24","author":"Bauer","year":"1983","journal-title":"Eur J Clin Pharmacol"},{"issue":"6","key":"10.1016\/j.diagmicrobio.2013.10.011_bb0045","first-page":"597","article-title":"Aminoglycosides\u201350 years on","volume":"39","author":"Begg","year":"1995","journal-title":"Br J Clin Pharmacol"},{"issue":"6","key":"10.1016\/j.diagmicrobio.2013.10.011_bb0050","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1111\/j.1365-2125.1995.tb05719.x","article-title":"A suggested approach to once-daily aminoglycoside dosing","volume":"39","author":"Begg","year":"1995","journal-title":"Br J Clin Pharmacol"},{"issue":"Suppl 1","key":"10.1016\/j.diagmicrobio.2013.10.011_bb0055","doi-asserted-by":"crossref","first-page":"35S","DOI":"10.1046\/j.1365-2125.2001.00377.x","article-title":"The therapeutic monitoring of antimicrobial agents","volume":"52","author":"Begg","year":"2001","journal-title":"Br J Clin Pharmacol"},{"issue":"5","key":"10.1016\/j.diagmicrobio.2013.10.011_bb0060","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1038\/clpt.2009.135","article-title":"Drug dosing in patients with impaired renal function","volume":"86","author":"Brater","year":"2009","journal-title":"Clin Pharmacol Ther"},{"issue":"4","key":"10.1016\/j.diagmicrobio.2013.10.011_bb0065","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1002\/cpt1979264508","article-title":"Tobramycin pharmacokinetics in morbidly obese patients","volume":"26","author":"Blouin","year":"1979","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.diagmicrobio.2013.10.011_bb0070","doi-asserted-by":"crossref","first-page":"593","DOI":"10.7326\/0003-4819-59-5-593","article-title":"Laboratory and clinical studies of gentamicin, new broad-spectrum antibiotic","volume":"59","author":"Bulger","year":"1963","journal-title":"Ann Intern Med"},{"issue":"12","key":"10.1016\/j.diagmicrobio.2013.10.011_bb0075","doi-asserted-by":"crossref","first-page":"3946","DOI":"10.1093\/ndt\/gfn379","article-title":"Obesity-induced glomerular hyperfiltration: its involvement in the pathogenesis of tubular sodium reabsorption","volume":"23","author":"Chagnac","year":"2008","journal-title":"Nephrol Dial Transplant"},{"issue":"5","key":"10.1016\/j.diagmicrobio.2013.10.011_bb0080","doi-asserted-by":"crossref","first-page":"773","DOI":"10.7326\/0003-4819-76-5-773","article-title":"Gentamicin therapy in renal failure: a nomogram for dosage","volume":"76","author":"Chan","year":"1972","journal-title":"Ann Intern Med"},{"issue":"3","key":"10.1016\/j.diagmicrobio.2013.10.011_bb0085","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1086\/313692","article-title":"National survey of extended-interval aminoglycoside dosing","volume":"30","author":"Chuck","year":"2000","journal-title":"Clin Infect Dis"},{"issue":"1","key":"10.1016\/j.diagmicrobio.2013.10.011_bb0090","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1159\/000180580","article-title":"Prediction of creatinine clearance from serum creatinine","volume":"16","author":"Cockcroft","year":"1976","journal-title":"Nephron"},{"issue":"1","key":"10.1016\/j.diagmicrobio.2013.10.011_bb0095","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1111\/j.1365-2125.2010.03793.x","article-title":"Tobramycin disposition in ICU patients receiving a once daily regimen: population approach and dosage simulations","volume":"71","author":"Conil","year":"2011","journal-title":"Br J Clin Pharmacol"},{"issue":"4","key":"10.1016\/j.diagmicrobio.2013.10.011_bb0100","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1128\/AAC.27.4.520","article-title":"Renal disposition of gentamicin, dibekacin, tobramycin, netilmicin, and amikacin in humans","volume":"27","author":"Contrepois","year":"1985","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.diagmicrobio.2013.10.011_bb0105","doi-asserted-by":"crossref","unstructured":"Craig WA, Redington J, Ebert SC. Pharmacodynamics of amikacin in vitro and in mouse thigh and lung infections. J Antimicrob Chemother 1991;27(Suppl C):29\u201340.","DOI":"10.1093\/jac\/27.suppl_C.29"},{"key":"10.1016\/j.diagmicrobio.2013.10.011_bb0110","unstructured":"Cubicin\u00ae, Daptomycin for injection. Full prescribing information. Cubist Pharmaceuticals, Inc., Lexington, MA, 2010."},{"issue":"8","key":"10.1016\/j.diagmicrobio.2013.10.011_bb0115","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1001\/jama.1972.03190340043010","article-title":"Correlation of serum creatinine concentrations and gentamicin half-life","volume":"219","author":"Cutler","year":"1972","journal-title":"JAMA"},{"issue":"5551","key":"10.1016\/j.diagmicrobio.2013.10.011_bb0120","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1136\/bmj.2.5551.535","article-title":"Dosage of gentamicin for pseudomonas infections","volume":"2","author":"Darrell","year":"1967","journal-title":"Br Med J"},{"issue":"1","key":"10.1016\/j.diagmicrobio.2013.10.011_bb0125","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1128\/AAC.8.1.58","article-title":"Gentamicin blood levels: a guide to nephrotoxicity","volume":"8","author":"Dahlgren","year":"1975","journal-title":"Antimicrob Agents Chemother"},{"issue":"10\u201311","key":"10.1016\/j.diagmicrobio.2013.10.011_bb0130","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1016\/j.clinbiochem.2012.03.030","article-title":"Population pharmacokinetics of four \u03b2-lactams in critically ill septic patients comedicated with amikacin","volume":"45","author":"Delattre","year":"2012","journal-title":"Clin Biochem"},{"issue":"5","key":"10.1016\/j.diagmicrobio.2013.10.011_bb0135","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1128\/AAC.41.5.1115","article-title":"Pharmacokinetics of gentamicin at traditional versus high doses: implications for once-daily aminoglycoside dosing","volume":"41","author":"Demczar","year":"1997","journal-title":"Antimicrob Agents Chemother"},{"issue":"1","key":"10.1016\/j.diagmicrobio.2013.10.011_bb0140","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1002\/cpt1974161part2274","article-title":"Drug dosage in patients with renal disease","volume":"16","author":"Dettli","year":"1974","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.diagmicrobio.2013.10.011_bb0145","unstructured":"Diem K, Lentner C. Documenta Geigy. Scientific Tables, 7th ed. Basel, Switzerland, J.R. Giegy, 1970:711."},{"issue":"6","key":"10.1016\/j.diagmicrobio.2013.10.011_bb0150","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1086\/520991","article-title":"Back to the future: using aminoglycosides again and how to dose them optimally","volume":"45","author":"Drusano","year":"2007","journal-title":"Clin Infect Dis"},{"issue":"6","key":"10.1016\/j.diagmicrobio.2013.10.011_bb0155","doi-asserted-by":"crossref","first-page":"2528","DOI":"10.1128\/AAC.01314-10","article-title":"Optimization of aminoglycoside therapy","volume":"55","author":"Drusano","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"issue":"11","key":"10.1016\/j.diagmicrobio.2013.10.011_bb0160","doi-asserted-by":"crossref","first-page":"785","DOI":"10.7326\/0003-4819-156-11-201203200-00391","article-title":"Estimating equations for glomerular filtration rate in the era of creatinine standardization: a systematic review","volume":"156","author":"Earley","year":"2012","journal-title":"Ann Intern Med"},{"issue":"1","key":"10.1016\/j.diagmicrobio.2013.10.011_bb0165","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1038\/sj.ijo.0800541","article-title":"Overweight and obesity in the United States: prevalence and trends, 1960\u20131994","volume":"22","author":"Flegal","year":"1998","journal-title":"Int J Obes Relat Metab Disord"},{"issue":"5","key":"10.1016\/j.diagmicrobio.2013.10.011_bb0170","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1001\/jama.2012.39","article-title":"Prevalence of obesity and trends in the distribution of body mass index among US adults, 1999\u20132010","volume":"307","author":"Flegal","year":"2012","journal-title":"JAMA"},{"issue":"5","key":"10.1016\/j.diagmicrobio.2013.10.011_bb0175","doi-asserted-by":"crossref","first-page":"537","DOI":"10.5301\/jn.5000009","article-title":"Glomerular filtration rate in early diabetes: ongoing discussions of causes and mechanisms","volume":"24","author":"Frische","year":"2011","journal-title":"J Nephrol"},{"key":"10.1016\/j.diagmicrobio.2013.10.011_bb0180","unstructured":"Gaspari F, Perico N, Remuzzi G. Measurement of glomerular filtration rate. Kidney Int 1997;63(Suppl):S151-4."},{"key":"10.1016\/j.diagmicrobio.2013.10.011_bb0185","unstructured":"Gentamicin sulfate, injection, USP. 2005. Full prescribing information. Hospira, Inc., Lake Forest, IL."},{"issue":"2","key":"10.1016\/j.diagmicrobio.2013.10.011_bb0190","doi-asserted-by":"crossref","first-page":"183","DOI":"10.7326\/0003-4819-85-2-183","article-title":"Gentamicin serum concentrations: pharmacokinetic predictions","volume":"85","author":"Hull","year":"1976","journal-title":"Ann Intern Med"},{"issue":"5","key":"10.1016\/j.diagmicrobio.2013.10.011_bb0195","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1128\/AAC.37.5.1025","article-title":"Nonparametric approach to population pharmacokinetics in oncology patients receiving aminoglycoside therapy","volume":"37","author":"Inciardi","year":"1993","journal-title":"Antimicrob Agents Chemother"},{"issue":"4","key":"10.1016\/j.diagmicrobio.2013.10.011_bb0200","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1016\/j.ijantimicag.2005.05.004","article-title":"Bicompartmental kinetics of tobramycin analysed with a wide range of covariates","volume":"26","author":"Inclan","year":"2005","journal-title":"Int J Antimicrob Agents"},{"issue":"10","key":"10.1016\/j.diagmicrobio.2013.10.011_bb0205","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.2165\/00003088-200544100-00004","article-title":"Quantification of lean bodyweight","volume":"44","author":"Janmahasatian","year":"2005","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.diagmicrobio.2013.10.011_bb0210","first-page":"148","article-title":"Clinical experience with gentamicin in gram-negative infections","volume":"161","author":"Jao","year":"1963","journal-title":"Antimicrob Agents Chemother"},{"issue":"7726","key":"10.1016\/j.diagmicrobio.2013.10.011_bb0215","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1016\/S0140-6736(71)92283-5","article-title":"Estimation of creatinine clearance from changing serum-creatinine levels","volume":"2","author":"Jelliffe","year":"1971","journal-title":"Lancet"},{"issue":"10","key":"10.1016\/j.diagmicrobio.2013.10.011_bb0220","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1001\/jama.1982.03330100028025","article-title":"Gentamicin dosing errors with four commonly used nomograms","volume":"248","author":"Lesar","year":"1982","journal-title":"JAMA"},{"issue":"9","key":"10.1016\/j.diagmicrobio.2013.10.011_bb0225","doi-asserted-by":"crossref","first-page":"604","DOI":"10.7326\/0003-4819-150-9-200905050-00006","article-title":"A new equation to estimate glomerular filtration rate","volume":"150","author":"Levey","year":"2009","journal-title":"Ann Intern Med"},{"issue":"1","key":"10.1016\/j.diagmicrobio.2013.10.011_bb0230","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1093\/infdis\/155.1.93","article-title":"Clinical response to aminoglycoside therapy: importance of the ratio of peak concentration to minimal inhibitory concentration","volume":"155","author":"Moore","year":"1987","journal-title":"J Infect Dis"},{"issue":"17","key":"10.1016\/j.diagmicrobio.2013.10.011_bb0235","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1056\/NEJM198710223171717","article-title":"Simplified calculation of body-surface area","volume":"317","author":"Mosteller","year":"1987","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.diagmicrobio.2013.10.011_bb0240","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1007\/s11908-012-0270-8","article-title":"Enterococcal endocarditis: can we win the war?","volume":"14","author":"Munita","year":"2012","journal-title":"Curr Infect Dis Rep"},{"issue":"3","key":"10.1016\/j.diagmicrobio.2013.10.011_bb0245","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1128\/AAC.39.3.650","article-title":"Experience with a once-daily aminoglycoside program administered to 2,184 adult patients","volume":"39","author":"Nicolau","year":"1995","journal-title":"Antimicrob Agents Chemother"},{"issue":"5906","key":"10.1016\/j.diagmicrobio.2013.10.011_bb0250","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1136\/bmj.1.5906.477","article-title":"Experience in monitoring gentamicin therapy during treatment of serious gram-negative sepsis","volume":"1","author":"Noone","year":"1974","journal-title":"Br Med J"},{"issue":"3","key":"10.1016\/j.diagmicrobio.2013.10.011_bb0255","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1345\/aph.1Q374","article-title":"The influence of body size descriptors on the estimation of kidney function in normal weight, overweight, obese, and morbidly obese adults","volume":"46","author":"Park","year":"2012","journal-title":"Ann Pharmacother"},{"issue":"9","key":"10.1016\/j.diagmicrobio.2013.10.011_bb0260","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1345\/aph.19381","article-title":"The origin of the \"ideal\" body weight equations","volume":"34","author":"Pai","year":"2000","journal-title":"Ann Pharmacother"},{"issue":"5","key":"10.1016\/j.diagmicrobio.2013.10.011_bb0265","doi-asserted-by":"crossref","first-page":"e53","DOI":"10.1053\/j.ackd.2010.05.010","article-title":"Estimating the glomerular filtration rate in obese adult patients for drug dosing","volume":"17","author":"Pai","year":"2010","journal-title":"Adv Chronic Kidney Dis"},{"issue":"9","key":"10.1016\/j.diagmicrobio.2013.10.011_bb0270","doi-asserted-by":"crossref","first-page":"4006","DOI":"10.1128\/AAC.00174-11","article-title":"Simplified estimation of aminoglycoside pharmacokinetics in underweight and obese adult patients","volume":"55","author":"Pai","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"issue":"9","key":"10.1016\/j.diagmicrobio.2013.10.011_bb0275","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1002\/j.1875-9114.2012.01108.x","article-title":"Drug dosing based on weight and body surface area: mathematical assumptions and limitations in obese adults","volume":"32","author":"Pai","year":"2012","journal-title":"Pharmacotherapy"},{"issue":"2","key":"10.1016\/j.diagmicrobio.2013.10.011_bb0280","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1093\/jac\/44.2.235","article-title":"Population pharmacokinetics of amikacin in patients with haematological malignancies","volume":"44","author":"Romano","year":"1999","journal-title":"J Antimicrob Chemother"},{"issue":"3","key":"10.1016\/j.diagmicrobio.2013.10.011_bb0285","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1046\/j.1365-2125.1998.00779.x","article-title":"Population pharmacokinetics of gentamicin in patients with cancer","volume":"46","author":"Rosario","year":"1998","journal-title":"Br J Clin Pharmacol"},{"issue":"5 Pt 1","key":"10.1016\/j.diagmicrobio.2013.10.011_bb0290","doi-asserted-by":"crossref","first-page":"612","DOI":"10.7326\/0003-4819-89-5-612","article-title":"Amikacin serum concentrations: prediction of levels and dosage guidelines","volume":"89","author":"Sarubbi","year":"1978","journal-title":"Ann Intern Med"},{"issue":"2","key":"10.1016\/j.diagmicrobio.2013.10.011_bb0295","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1007\/BF01086153","article-title":"Pharmacokinetics of dosing regimens which utilize multiple intravenous infusions: gentamicin in burn patients","volume":"4","author":"Sawchuk","year":"1976","journal-title":"J Pharmacokinet Biopharm"},{"issue":"4","key":"10.1016\/j.diagmicrobio.2013.10.011_bb0300","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1093\/infdis\/138.4.499","article-title":"A controlled investigation of the pharmacokinetics of gentamicin and tobramycin in obese subjects","volume":"138","author":"Schwartz","year":"1978","journal-title":"J Infect Dis"},{"issue":"7","key":"10.1016\/j.diagmicrobio.2013.10.011_bb0310","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1002\/j.1552-4604.1981.tb01769.x","article-title":"Effect of obesity on gentamicin pharmacokinetics","volume":"21","author":"Sketris","year":"1981","journal-title":"J Clin Pharmacol"},{"issue":"5","key":"10.1016\/j.diagmicrobio.2013.10.011_bb0360","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1038\/clpt.2009.187","article-title":"Continuing the use of the Cockcroft-Gault equation for drug dosing in patients with impaired renal function","volume":"86","author":"Spruill","year":"2009","journal-title":"Clin Pharmacol Ther"},{"issue":"5","key":"10.1016\/j.diagmicrobio.2013.10.011_bb0320","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1038\/clpt.2009.124","article-title":"Use of the MDRD study equation to estimate kidney function for drug dosing","volume":"86","author":"Stevens","year":"2009","journal-title":"Clin Pharmacol Ther"},{"issue":"5","key":"10.1016\/j.diagmicrobio.2013.10.011_bb0325","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1038\/ki.2010.462","article-title":"Evaluation of the Chronic Kidney Disease Epidemiology Collaboration equation for estimating the glomerular filtration rate in multiple ethnicities","volume":"79","author":"Stevens","year":"2011","journal-title":"Kidney Int"},{"issue":"4","key":"10.1016\/j.diagmicrobio.2013.10.011_bb0330","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1128\/AAC.42.4.849","article-title":"Population pharmacokinetic study of amikacin administered once or twice daily to febrile, severely neutropenic adults","volume":"42","author":"Tod","year":"1998","journal-title":"Antimicrob Agents Chemother"},{"issue":"6","key":"10.1016\/j.diagmicrobio.2013.10.011_bb0335","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1111\/j.1365-2885.2004.00602.x","article-title":"Volumes of distribution","volume":"27","author":"Toutain","year":"2004","journal-title":"J Vet Pharmacol Ther"},{"issue":"6","key":"10.1016\/j.diagmicrobio.2013.10.011_bb0340","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1023\/B:PHAM.0000029286.45788.ad","article-title":"Creatinine transport by basolateral organic cation transporter hOCT2 in the human kidney","volume":"21","author":"Urakami","year":"2004","journal-title":"Pharm Res"},{"key":"10.1016\/j.diagmicrobio.2013.10.011_bb0345","unstructured":"Vancomycin hydrochloride, vancomycin hydrochloride for injection. Full prescribing information. Baxter Healthcare Corporation, Deerfeild, IL, 2008."},{"key":"10.1016\/j.diagmicrobio.2013.10.011_bb0350","unstructured":"Vibativ\u00ae, Televancin for injection. Full prescribing Information. Theravance, Inc. South San Francisco, CA, 2012."},{"issue":"3","key":"10.1016\/j.diagmicrobio.2013.10.011_bb0355","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/j.ijantimicag.2003.07.010","article-title":"Population pharmacokinetics of gentamicin in hospitalized patients receiving once-daily dosing","volume":"23","author":"Xuan","year":"2004","journal-title":"Int J Antimicrob Agents"}],"container-title":["Diagnostic Microbiology and Infectious Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0732889313005488?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0732889313005488?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,7,31]],"date-time":"2019-07-31T02:33:29Z","timestamp":1564540409000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0732889313005488"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,2]]},"references-count":70,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2014,2]]}},"alternative-id":["S0732889313005488"],"URL":"https:\/\/doi.org\/10.1016\/j.diagmicrobio.2013.10.011","relation":{},"ISSN":["0732-8893"],"issn-type":[{"value":"0732-8893","type":"print"}],"subject":[],"published":{"date-parts":[[2014,2]]}}}